0 XP   0   0   0

Amylyx Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyse Amylyx together

PenkeI guess you are interested in Amylyx Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Amylyx Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Amylyx Pharmaceuticals Inc

I send you an email if I find something interesting about Amylyx Pharmaceuticals Inc.

Quick analysis of Amylyx (30 sec.)










1. Valuation of Amylyx (5 min.)




Live pricePrice per share (EOD)

$25.56

2. Growth of Amylyx (5 min.)




Is Amylyx growing?

Current yearPrevious yearGrowGrow %
How rich?$352.6m$34.5m$222.9m86.6%

How much money is Amylyx making?

Current yearPrevious yearGrowGrow %
Making money-$37.2m-$46m$8.8m?
Net Profit Margin-3,943.6%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Amylyx (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#175 / 1215

Most Revenue
#211 / 1215

Most Profit
#1008 / 1215

Most Efficient
#1061 / 1215


Fundamentals of Amylyx

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

1.1. Profitability of Amylyx Pharmaceuticals Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Amylyx earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Amylyx to the Biotechnology industry mean.
  • A Net Profit Margin of 2.2% means that $0.02 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Amylyx Pharmaceuticals Inc:

  • The MRQ is 2.2%. The company is making a profit. +1
  • The TTM is -3,943.6%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ2.2%TTM-3,943.6%+3,945.8%
TTM-3,943.6%YOY--3,943.6%
TTM-3,943.6%5Y-1,577.4%-2,366.2%
5Y-1,577.4%10Y-1,577.4%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.2%-193.4%+195.6%
TTM-3,943.6%-273.6%-3,670.0%
YOY--315.2%+315.2%
5Y-1,577.4%-539.0%-1,038.4%
10Y-1,577.4%-664.9%-912.5%
1.1.2. Return on Assets

Shows how efficient Amylyx is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Amylyx to the Biotechnology industry mean.
  • 0.4% Return on Assets means that Amylyx generated $0.00 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Amylyx Pharmaceuticals Inc:

  • The MRQ is 0.4%. Using its assets, the company is inefficient in making profit. -1
  • The TTM is -16.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ0.4%TTM-16.0%+16.4%
TTM-16.0%YOY-74.4%+58.4%
TTM-16.0%5Y-53.7%+37.7%
5Y-53.7%10Y-53.7%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4%-12.3%+12.7%
TTM-16.0%-12.4%-3.6%
YOY-74.4%-10.9%-63.5%
5Y-53.7%-15.3%-38.4%
10Y-53.7%-17.6%-36.1%
1.1.3. Return on Equity

Shows how efficient Amylyx is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Amylyx to the Biotechnology industry mean.
  • 0.4% Return on Equity means Amylyx generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Amylyx Pharmaceuticals Inc:

  • The MRQ is 0.4%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is -19.4%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ0.4%TTM-19.4%+19.8%
TTM-19.4%YOY-5.0%-14.4%
TTM-19.4%5Y-9.7%-9.6%
5Y-9.7%10Y-9.7%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4%-15.2%+15.6%
TTM-19.4%-15.5%-3.9%
YOY-5.0%-13.1%+8.1%
5Y-9.7%-20.4%+10.7%
10Y-9.7%-20.9%+11.2%

1.2. Operating Efficiency of Amylyx Pharmaceuticals Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Amylyx is operating .

  • Measures how much profit Amylyx makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Amylyx to the Biotechnology industry mean.
  • An Operating Margin of 2.0% means the company generated $0.02  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Amylyx Pharmaceuticals Inc:

  • The MRQ is 2.0%. The company is operating less efficient.
  • The TTM is -4,012.8%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ2.0%TTM-4,012.8%+4,014.8%
TTM-4,012.8%YOY--4,012.8%
TTM-4,012.8%5Y-1,605.1%-2,407.7%
5Y-1,605.1%10Y-1,605.1%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.0%-316.7%+318.7%
TTM-4,012.8%-267.4%-3,745.4%
YOY--333.8%+333.8%
5Y-1,605.1%-517.0%-1,088.1%
10Y-1,605.1%-624.7%-980.4%
1.2.2. Operating Ratio

Measures how efficient Amylyx is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.03 means that the operating costs are $1.03 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Amylyx Pharmaceuticals Inc:

  • The MRQ is 1.029. The company is inefficient in keeping operating costs low. -1
  • The TTM is 40.891. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.029TTM40.891-39.862
TTM40.891YOY-+40.891
TTM40.8915Y16.356+24.534
5Y16.35610Y16.3560.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0292.989-1.960
TTM40.8913.644+37.247
YOY-4.537-4.537
5Y16.3566.411+9.945
10Y16.3568.312+8.044

1.3. Liquidity of Amylyx Pharmaceuticals Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Amylyx is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 8.06 means the company has $8.06 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Amylyx Pharmaceuticals Inc:

  • The MRQ is 8.059. The company is very able to pay all its short-term debts. +2
  • The TTM is 7.372. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ8.059TTM7.372+0.687
TTM7.372YOY6.049+1.324
TTM7.3725Y5.555+1.818
5Y5.55510Y5.5550.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ8.0594.559+3.500
TTM7.3724.993+2.379
YOY6.0496.149-0.100
5Y5.5556.306-0.751
10Y5.5556.588-1.033
1.3.2. Quick Ratio

Measures if Amylyx is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Amylyx to the Biotechnology industry mean.
  • A Quick Ratio of 12.00 means the company can pay off $12.00 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Amylyx Pharmaceuticals Inc:

  • The MRQ is 12.001. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 11.319. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ12.001TTM11.319+0.683
TTM11.319YOY8.535+2.784
TTM11.3195Y8.117+3.202
5Y8.11710Y8.1170.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ12.0013.874+8.127
TTM11.3194.499+6.820
YOY8.5355.772+2.763
5Y8.1175.816+2.301
10Y8.1176.032+2.085

1.4. Solvency of Amylyx Pharmaceuticals Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Amylyx assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Amylyx to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.14 means that Amylyx assets are financed with 13.6% credit (debt) and the remaining percentage (100% - 13.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Amylyx Pharmaceuticals Inc:

  • The MRQ is 0.136. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.154. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.136TTM0.154-0.018
TTM0.154YOY1.992-1.838
TTM0.1545Y2.005-1.851
5Y2.00510Y2.0050.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1360.311-0.175
TTM0.1540.298-0.144
YOY1.9920.269+1.723
5Y2.0050.377+1.628
10Y2.0050.409+1.596
1.4.2. Debt to Equity Ratio

Measures if Amylyx is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Amylyx to the Biotechnology industry mean.
  • A Debt to Equity ratio of 15.7% means that company has $0.16 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Amylyx Pharmaceuticals Inc:

  • The MRQ is 0.157. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.184. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.157TTM0.184-0.027
TTM0.184YOY0.035+0.149
TTM0.1845Y0.087+0.096
5Y0.08710Y0.0870.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1570.363-0.206
TTM0.1840.362-0.178
YOY0.0350.277-0.242
5Y0.0870.425-0.338
10Y0.0870.463-0.376

2. Market Valuation of Amylyx Pharmaceuticals Inc

2. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Amylyx generates.

  • Above 15 is considered overpriced but always compare Amylyx to the Biotechnology industry mean.
  • A PE ratio of 1,321.77 means the investor is paying $1,321.77 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Amylyx Pharmaceuticals Inc:

  • The EOD is 1,151.478. Seems overpriced? -1
  • The MRQ is 1,321.767. Seems overpriced? -1
  • The TTM is 301.134. Seems overpriced? -1
Trends
Current periodCompared to+/- 
EOD1,151.478MRQ1,321.767-170.289
MRQ1,321.767TTM301.134+1,020.633
TTM301.134YOY-4.510+305.644
TTM301.1345Y118.649+182.484
5Y118.64910Y118.6490.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1,151.478-6.478+1,157.956
MRQ1,321.767-7.165+1,328.932
TTM301.134-8.420+309.554
YOY-4.510-19.867+15.357
5Y118.649-18.328+136.977
10Y118.649-18.055+136.704
2.2. Price Earnings to Growth Ratio

Measures the predicted future growth of Amylyx.

  • Lower is better.
  • A PEG ratio of 1 means the market price of the stock and the expected future earnings are on par.

Let's take a look of the Price Earnings to Growth Ratio trends of Amylyx Pharmaceuticals Inc:

  • The MRQ is 649.543. Seems overpriced? -1
  • The TTM is 134.712. Seems overpriced? -1
Trends
Current periodCompared to+/- 
MRQ649.543TTM134.712+514.831
TTM134.712YOY-57.845+192.557
TTM134.7125Y96.201+38.511
5Y96.20110Y96.2010.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ649.543-4.292+653.835
TTM134.712-6.108+140.820
YOY-57.845-13.925-43.920
5Y96.201-12.525+108.726
10Y96.201-11.713+107.914

2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Amylyx is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 5.90 means the investor is paying $5.90 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Amylyx Pharmaceuticals Inc:

  • The EOD is 5.136. Seems overpriced? -1
  • The MRQ is 5.896. Seems overpriced? -1
  • The TTM is 8.256. Seems overpriced? -1
Trends
Current periodCompared to+/- 
EOD5.136MRQ5.896-0.760
MRQ5.896TTM8.256-2.360
TTM8.256YOY0.896+7.360
TTM8.2565Y3.661+4.595
5Y3.66110Y3.6610.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD5.1361.890+3.246
MRQ5.8962.024+3.872
TTM8.2562.335+5.921
YOY0.8963.965-3.069
5Y3.6613.738-0.077
10Y3.6614.002-0.341
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Amylyx Pharmaceuticals Inc.

3.1. Institutions holding Amylyx Pharmaceuticals Inc

Institutions are holding 81.986% of the shares of Amylyx Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2022-12-31Perceptive Advisors LLC9.07166.3171608833361630011.2627
2023-03-31Vanguard Group Inc7.07360.003647473413888498.9216
2022-12-31Viking Global Investors LP6.90560.85734634606-1135930-19.685
2022-12-31BlackRock Inc5.38920.00423616926132109257.543
2022-12-31Deerfield Management Co4.01262.0597269300026930000
2022-12-31Point72 Asset Management, L.P.3.17070.267321279601660999355.704
2022-12-31Boxer Capital LLC3.10524.0594208400000
2023-03-31D. E. Shaw & Co LP3.01330.0635202237063863846.1533
2022-12-31Federated Hermes Inc2.40610.165161484528584521.5083
2022-12-31Rock Springs Capital Management LP1.83221.09331229637825900204.5639
2023-03-31State Street Corporation1.58870.00181066238-9374-0.8715
2022-12-31Goldman Sachs Group Inc1.5440.00861036270656871173.1346
2023-03-31Adage Capital Partners Gp LLC1.50090.06631007336-901865-47.2378
2023-03-31Emerald Advisers, LLC1.44951.368897283513592616.2414
2022-12-31Millennium Management LLC1.28050.0176859415-61713-6.6997
2022-12-31Geode Capital Management, LLC1.27230.004485391321835734.3568
2022-12-31Falcon Edge Capital LP1.22365.541482122012058517.2108
2023-03-31Emerald Mutual Fund Advisers Trust1.17651.368578959113457620.5455
2022-12-31Balyasny Asset Management LLC0.96190.0653645553454219237.3959
2022-12-31Nuveen Asset Management, LLC0.88810.008559605423936767.1084
Total 58.866123.341639507443+8281642+21.0%

3.2. Funds holding Amylyx Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-04-30Vanguard Total Stock Mkt Idx Inv2.46550.003716547027950.0481
2023-03-31Vanguard Instl Ttl Stck Mkt Idx Tr2.46430.003916539071475749.7969
2023-04-30Vanguard Small Cap Index2.06760.03361387659-342-0.0246
2023-04-28iShares Russell 2000 ETF1.61180.06311081711-12480-1.1406
2023-04-30Vanguard Small Cap Growth Index Inv1.18590.078179592131500.3973
2023-03-31Federated Hermes Kaufmann Growth1.15420.474977463700
2023-03-31Federated Hermes Kaufmann R1.15420.475277463700
2023-03-31Federated Hermes Kaufmann Small Cap Grow1.08990.497873146200
2023-03-31Federated Hermes Kaufmann Small Cap A1.08990.498273146200
2023-01-31Biotech Growth Ord0.91484.64616139596139590
2023-04-30Vanguard Extended Market Index Investor0.81070.01855440724130.076
2023-02-28Fidelity® Small Cap Index0.62960.071342255865491.5742
2023-03-31Emerald Growth A0.62711.37964208746817719.3302
2023-04-28iShares Russell 2000 Value ETF0.61190.10684106387530.1837
2023-03-31CREF Stock R10.50570.00933941300
2023-04-30Voya MidCap Opportunities Port I0.48960.941332858612047757.8913
2023-04-28iShares Biotechnology ETF0.46130.1115309620-1792-0.5754
2023-04-30Principal SmallCap Growth I Instl0.39750.3332266763-64-0.024
2022-10-31Pictet-Biotech P USD0.38960.5592614442614440
2023-04-30State St Russell Sm/Mid Cp® Indx NL Cl C0.38120.023125584900
Total 20.502310.327913759874+1208613+8.8%

3.3. Insider Transactions

Insiders are holding 23.461% of the shares of Amylyx Pharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-05-16James M FratesSELL3250026.9455676
2023-05-15Patrick D YeramianSELL1196529.03208417
2023-04-17Patrick D YeramianSELL4957930.54208417
2023-03-29Morningside Venture InvestmentSELL2904830.456997302
2023-03-27Morningside Venture InvestmentSELL6096430.57126350
2023-03-21Morningside Venture InvestmentSELL6344831.917187314
2023-03-16George M Milne JrSELL3500031.89862021
2023-03-16James M FratesSELL3250031.891509
2023-03-16Justin B KleeSELL10000031.862792617
2023-03-16Morningside Venture InvestmentSELL912232.557250762
2023-03-16Patrick D YeramianSELL5462731.87149672
2023-03-14Morningside Venture InvestmentSELL7071434.547409884
2023-03-02Morningside Venture InvestmentSELL5000033.757480598
2023-02-24Gina MazzarielloSELL358634.4937414
2023-02-22Morningside Venture InvestmentSELL5000034.737530598
2022-09-08Global Investors Lp VikingSELL70000029.372075470

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Amylyx Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.0940.347-127%1.145-108%0.498-119%0.498-119%
Book Value Growth--1.0351.237-16%1.646-37%1.392-26%1.392-26%
Book Value Per Share--4.9763.765+32%0.515+867%1.513+229%1.513+229%
Book Value Per Share Growth--0.9811.223-20%1.646-40%1.386-29%1.386-29%
Current Ratio--8.0597.372+9%6.049+33%5.555+45%5.555+45%
Debt To Asset Ratio--0.1360.154-12%1.992-93%2.005-93%2.005-93%
Debt To Equity Ratio--0.1570.184-15%0.035+351%0.087+80%0.087+80%
Dividend Per Share----0%-0%-0%-0%
Eps--0.022-0.555+2599%-0.452+2137%-0.437+2069%-0.437+2069%
Eps Growth--2.0351.279+59%0.312+552%1.086+87%1.086+87%
Free Cash Flow Per Share---0.075-0.545+626%-0.385+413%-0.404+438%-0.404+438%
Free Cash Flow Per Share Growth--1.9001.167+63%0.641+196%0.870+118%0.870+118%
Free Cash Flow To Equity Per Share---0.0601.062-106%0.854-107%0.775-108%0.775-108%
Free Cash Flow To Equity Per Share Growth---0.0221.516-101%4.579-100%3.119-101%3.119-101%
Gross Profit Margin--1.0001.091-8%1.0000%1.036-4%1.036-4%
Intrinsic Value_10Y_max---79.212--------
Intrinsic Value_10Y_min---66.537--------
Intrinsic Value_1Y_max---3.018--------
Intrinsic Value_1Y_min---2.961--------
Intrinsic Value_3Y_max---12.817--------
Intrinsic Value_3Y_min---12.160--------
Intrinsic Value_5Y_max---27.136--------
Intrinsic Value_5Y_min---24.865--------
Net Profit Margin--0.022-39.436+179174%-+100%-15.774+71730%-15.774+71730%
Operating Margin--0.020-40.128+204397%-+100%-16.051+81819%-16.051+81819%
Operating Ratio--1.02940.891-97%-+100%16.356-94%16.356-94%
Pb Ratio5.136-15%5.8968.256-29%0.896+558%3.661+61%3.661+61%
Pe Ratio1151.478-15%1321.767301.134+339%-4.510+100%118.649+1014%118.649+1014%
Peg Ratio--649.543134.712+382%-57.845+109%96.201+575%96.201+575%
Price Per Share25.560-15%29.34028.425+3%3.213+813%12.655+132%12.655+132%
Price To Total Gains Ratio-272.114+13%-312.357-91.344-71%5.651-5628%-71.945-77%-71.945-77%
Profit Growth--2.0371.280+59%0.302+575%0.716+185%0.716+185%
Quick Ratio--12.00111.319+6%8.535+41%8.117+48%8.117+48%
Return On Assets--0.004-0.160+4260%-0.744+19398%-0.537+14038%-0.537+14038%
Return On Equity--0.004-0.194+4441%-0.050+1213%-0.097+2282%-0.097+2282%
Revenue Growth--3.26433.349-90%--33.349-90%33.349-90%
Total Gains Per Share---0.0940.347-127%1.145-108%0.498-119%0.498-119%
Total Gains Per Share Growth---0.0321.668-102%3.211-101%2.156-101%2.156-101%
Usd Book Value--352648000.000257518000.000+37%34583500.000+920%103495600.000+241%103495600.000+241%
Usd Book Value Change Per Share---0.0940.347-127%1.145-108%0.498-119%0.498-119%
Usd Book Value Per Share--4.9763.765+32%0.515+867%1.513+229%1.513+229%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps--0.022-0.555+2599%-0.452+2137%-0.437+2069%-0.437+2069%
Usd Free Cash Flow---5322000.000-36685750.000+589%-25867750.000+386%-27191000.000+411%-27191000.000+411%
Usd Free Cash Flow Per Share---0.075-0.545+626%-0.385+413%-0.404+438%-0.404+438%
Usd Free Cash Flow To Equity Per Share---0.0601.062-106%0.854-107%0.775-108%0.775-108%
Usd Price Per Share25.560-15%29.34028.425+3%3.213+813%12.655+132%12.655+132%
Usd Profit--1573000.000-37238500.000+2467%-46092000.000+3030%-35809000.000+2376%-35809000.000+2376%
Usd Revenue--71428000.00023414500.000+205%-+100%9365800.000+663%9365800.000+663%
Usd Total Gains Per Share---0.0940.347-127%1.145-108%0.498-119%0.498-119%
 EOD+4 -1MRQTTM+24 -16YOY+21 -175Y+22 -1810Y+22 -18

4.2. Fundamental Score

Let's check the fundamental score of Amylyx Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-151,151.478
Price to Book Ratio (EOD)Between0-15.136
Net Profit Margin (MRQ)Greater than00.022
Operating Margin (MRQ)Greater than00.020
Quick Ratio (MRQ)Greater than112.001
Current Ratio (MRQ)Greater than18.059
Debt to Asset Ratio (MRQ)Less than10.136
Debt to Equity Ratio (MRQ)Less than10.157
Return on Equity (MRQ)Greater than0.150.004
Return on Assets (MRQ)Greater than0.050.004
Total6/10 (60.0%)

4.3. Technical Score

Let's check the technical score of Amylyx Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose25.310
Total0/1 (0.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-03-312022-06-302022-09-302022-12-312023-03-31
Accumulated Other Comprehensive Income  -151-45-196-529-725639-8611125
Income before Tax  -47,702-6,191-53,89312-53,88111,756-42,12543,5281,403
Net Income  -47,848-6,219-54,067311-53,75611,052-42,70444,2771,573
EBIT  -47,814-6,439-54,253-428-54,68110,088-44,59345,9961,403
Net Income from Continuing Operations  -47,848-6,219-54,067311-53,75611,052-42,70444,2771,573
Net Income Applicable to Common Shares  -47,848-6,219-54,067311-53,75611,052-42,70444,2771,573



Latest Balance Sheet

Balance Sheet of 2023-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets407,958
Total Liabilities55,310
Total Stockholder Equity352,648
 As reported
Total Liabilities 55,310
Total Stockholder Equity+ 352,648
Total Assets = 407,958

Assets

Total Assets407,958
Total Current Assets399,126
Long-term Assets399,126
Total Current Assets
Cash And Cash Equivalents 114,563
Short-term Investments 231,111
Net Receivables 17,555
Inventory 23,148
Other Current Assets 12,749
Total Current Assets  (as reported)399,126
Total Current Assets  (calculated)399,126
+/-0
Long-term Assets
Property Plant Equipment 7,647
Long-term Assets Other 1,185
Long-term Assets  (as reported)8,832
Long-term Assets  (calculated)8,832
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities49,523
Long-term Liabilities5,787
Total Stockholder Equity352,648
Total Current Liabilities
Short-term Debt 2,093
Accounts payable 10,770
Other Current Liabilities 36,660
Total Current Liabilities  (as reported)49,523
Total Current Liabilities  (calculated)49,523
+/-0
Long-term Liabilities
Capital Lease Obligations 5,787
Long-term Liabilities  (as reported)5,787
Long-term Liabilities  (calculated)5,787
+/-0
Total Stockholder Equity
Common Stock7
Retained Earnings -352,647
Accumulated Other Comprehensive Income 25
Capital Surplus 705,263
Total Stockholder Equity (as reported)352,648
Total Stockholder Equity (calculated)352,648
+/-0
Other
Capital Stock7
Cash and Short Term Investments 345,674
Common Stock Shares Outstanding 70,864
Common Stock Total Equity7
Liabilities and Stockholders Equity 407,958
Net Debt -108,776
Net Invested Capital 352,648
Net Tangible Assets 352,648
Net Working Capital 349,603
Short Long Term Debt Total 5,787



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-31
> Total Assets 
14,104
0
0
130,460
105,614
274,438
225,240
181,443
391,453
407,958
407,958391,453181,443225,240274,438105,614130,4600014,104
   > Total Current Assets 
13,639
0
0
129,942
104,951
265,488
216,139
172,199
382,133
399,126
399,126382,133172,199216,139265,488104,951129,9420013,639
       Cash And Cash Equivalents 
12,877
0
0
76,677
50,191
110,403
67,440
107,734
346,945
114,563
114,563346,945107,73467,440110,40350,19176,6770012,877
       Short-term Investments 
0
0
0
49,025
45,927
144,802
139,241
54,859
284,419
231,111
231,111284,41954,859139,241144,80245,92749,025000
       Net Receivables 
0
0
0
0
0
0
0
137
15,306
17,555
17,55515,3061370000000
       Other Current Assets 
762
0
0
4,240
8,833
10,283
9,458
8,906
10,113
12,749
12,74910,1138,9069,45810,2838,8334,24000762
   > Long-term Assets 
465
0
0
518
663
8,950
9,101
9,244
9,320
8,832
8,8329,3209,2449,1018,95066351800465
       Property Plant Equipment 
151
0
0
329
474
8,075
8,226
8,069
8,135
7,647
7,6478,1358,0698,2268,07547432900151
       Other Assets 
314
0
0
0
189
875
9,101
1,175
0
0
001,1759,101875189000314
> Total Liabilities 
80,829
0
0
254,530
17,431
33,492
32,451
37,415
50,846
55,310
55,31050,84637,41532,45133,49217,431254,5300080,829
   > Total Current Liabilities 
7,326
0
0
15,146
17,396
27,706
27,164
32,647
46,609
49,523
49,52346,60932,64727,16427,70617,39615,146007,326
       Short-term Debt 
0
0
0
263
0
1,405
1,787
1,990
2,040
2,093
2,0932,0401,9901,7871,4050263000
       Short Long Term Debt 
0
0
0
263
0
0
0
0
0
0
000000263000
       Accounts payable 
3,613
0
0
3,026
4,372
10,045
8,117
7,052
46,609
10,770
10,77046,6097,0528,11710,0454,3723,026003,613
       Other Current Liabilities 
3,713
0
0
11,857
13,024
16,256
17,260
23,605
-2,040
36,660
36,660-2,04023,60517,26016,25613,02411,857003,713
   > Long-term Liabilities 
73,503
0
0
239,384
35
5,786
5,287
4,768
4,237
5,787
5,7874,2374,7685,2875,78635239,3840073,503
       Long term Debt 
1,425
0
0
0
0
0
0
0
0
0
0000000001,425
       Capital Lease Obligations Min Short Term Debt
0
0
0
-263
0
5,786
5,287
4,768
4,237
3,694
3,6944,2374,7685,2875,7860-263000
       Other Liabilities 
16
0
0
0
35
0
7,074
0
0
0
0007,07403500016
       Long-term Liabilities Other 
0
0
0
0
0
5,786
5,287
4,768
4,237
3,694
3,6944,2374,7685,2875,78600000
> Total Stockholder Equity
-66,725
0
0
-124,070
-151,168
240,946
192,789
144,028
340,607
352,648
352,648340,607144,028192,789240,946-151,168-124,07000-66,725
   Common Stock
1
0
0
1
1
6
6
6
7
7
7766611001
   Retained Earnings -352,647-354,220-311,516-257,760-203,693-155,845-127,50100-67,914
   Capital Surplus 
0
0
0
0
0
444,784
450,739
456,263
694,906
705,263
705,263694,906456,263450,739444,78400000
   Treasury Stock0000000000
   Other Stockholders Equity 
1,188
0
0
3,431
4,667
444,784
225,499
274,820
694,906
297,305
297,305694,906274,820225,499444,7844,6673,431001,188



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2022-12-31)

Gross Profit (+$)
totalRevenue22,230
Cost of Revenue-2,993
Gross Profit19,23719,237
 
Operating Income (+$)
Gross Profit19,237
Operating Expense-220,578
Operating Income-201,341-201,341
 
Operating Expense (+$)
Research Development93,450
Selling General Administrative127,128
Selling And Marketing Expenses-
Operating Expense220,578220,578
 
Net Interest Income (+$)
Interest Income4,291
Interest Expense-4,291
Other Finance Cost-4,291
Net Interest Income4,291
 
Pretax Income (+$)
Operating Income-201,341
Net Interest Income4,291
Other Non-Operating Income Expenses3,740
Income Before Tax (EBT)-197,601-205,081
EBIT - interestExpense = -205,632
-197,601
-194,084
Interest Expense4,291
Earnings Before Interest and Taxes (EBIT)-201,341-193,310
Earnings Before Interest and Taxes (EBITDA)-201,341
 
After tax Income (+$)
Income Before Tax-197,601
Tax Provision-774
Net Income From Continuing Ops-198,375-198,375
Net Income-198,375
Net Income Applicable To Common Shares-198,375
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses223,571
Total Other Income/Expenses Net3,740-8,031
 

Technicals of Amylyx

1. Trend Indicators

1.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Amylyx Pharmaceuticals Inc Daily Moving Averages ChartAmylyx Pharmaceuticals Inc Daily Moving Averages Chart
1.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Let's take a look of the Moving Average Convergence/Divergence (MACD) of Amylyx Pharmaceuticals Inc:

    Amylyx Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartAmylyx Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
    1.3 Directional Movement Index (DMI)

    The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index).

    The ADX helps you determine the strength of a trend. Let's take a look of the ADX of Amylyx Pharmaceuticals Inc:

    • The ADX is .
    • The ADX is declining, there is no upcoming trend indication. -1
    • The +DI is lower than the -DI. The current trend is down. -2
    Amylyx Pharmaceuticals Inc Daily Directional Movement Index (DMI) ChartAmylyx Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
    1.4 Parabolic SAR

    Shows the current trend and potential entry and exit signals.

    • Parabolic SAR (stop and reverse) is a lagging trend indicator.
    • Shows the current trend.
    • Shows potential entry signals.
    • Shows  potential exit signals.
    • Can be used to place trailing stoplosses..
  • The price has crossed the Parabolic SAR to the upside. The trend is reversing to an up trend. +1
  • Amylyx Pharmaceuticals Inc Daily Parabolic SAR ChartAmylyx Pharmaceuticals Inc Daily Parabolic SAR Chart

    2. Momentum Indicators

    2.1 Relative Strength Index (RSI)

    Measures the speed and change of price movements.

    • Leading momentum indicator, meaning the signals are instant.
    • Ranges between 0 and 100.
    • Above 70 is considered overbought.
    • Below 30 is considered oversold.
    • Above or below 50 can also be used to determine price trend or support and resistance.
    • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
    • Can be used in many different ways
    • The RSI is below 50. -1
    • The RSI is below 30 and oversold. +2
    Amylyx Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartAmylyx Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
    2.2 Stochastic Oscillator

    Compares a certain price to multiple prices ranging over time.

    • Leading momentum indicator, meaning the signals are instant.
    • Used to determine overbought and oversold areas much like the RSI.
    • Ranges between 0 and 100.
    • Above 80 is considered overbought.
    • Below 20 is considered oversold.
    • Consists of two lines named K and D.
    • K compares the highest high and lowest low on the selected price range.
    • The D line is a moving average of the K line.
    • Can be used to spot divergences
    • The Stochastic is below 50. -1
    • The Stochastic is below 30 and oversold. +2
    Amylyx Pharmaceuticals Inc Daily Stochastic Oscillator ChartAmylyx Pharmaceuticals Inc Daily Stochastic Oscillator Chart
    2.3 Commodity Channel Index (CCI)
    Amylyx Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartAmylyx Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
    2.4 Chande Momentum Oscillator (CMO)
    Amylyx Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartAmylyx Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
    2.5 Williams %R
    Amylyx Pharmaceuticals Inc Daily Williams %R ChartAmylyx Pharmaceuticals Inc Daily Williams %R Chart

    3. Volatility Indicators

    3.1 Bollinger Bands
    Amylyx Pharmaceuticals Inc Daily Bollinger Bands ChartAmylyx Pharmaceuticals Inc Daily Bollinger Bands Chart
    3.2 Average True Range (ATR)
    Amylyx Pharmaceuticals Inc Daily Average True Range (ATR) ChartAmylyx Pharmaceuticals Inc Daily Average True Range (ATR) Chart

    4. Volume Indicators

    4.1 On-Balance Volume (OBV)
    Amylyx Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartAmylyx Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
    4.2 Money Flow Index (MFI)
    Amylyx Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartAmylyx Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart

    5. Summary

    5.1. Notifications

    TypeNotificationDate
    PenkeCurrently no notifications for Amylyx Pharmaceuticals Inc.

    5.2. Trading Signals

    DateIndicatorEntry signalExit signal
    2023-05-23STOCH LONG ENTRY SHORT CLOSE20 crossover to upside
    2023-05-24DMI LONG ENTRY SHORT CLOSE
    2023-05-25ATR LONG ENTRY SHORT CLOSE
    MFI20 crossover to upside
    2023-05-26RSI LONG ENTRY SHORT CLOSE30 crossover to upside
    2023-05-30CMO SHORT ENTRY LONG CLOSE-50 crossover to downside
    MFI20 crossover to downside
    2023-06-01WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
    2023-06-02CCI SHORT ENTRY LONG CLOSE-100 crossover to downside

    5.2. Technical Score

    Let's check the technical score of Amylyx Pharmaceuticals Inc based on Penke's default Symbol scanner.

    Penke's Symbol Scanner

      
      
    IndicatorConditionValue
    OpenGreater thanClose25.310
    Total0/1 (0.0%)

    Comments

    Join the conversation.

    Leave a comment

    Stay informed about Amylyx Pharmaceuticals Inc.

    Receive notifications about Amylyx Pharmaceuticals Inc in your mailbox!